Shares of Recursion Pharmaceuticals, Inc. (RXRX) gained over 12% on Monday morning after the drug developer announced completion of Nvidia-powered supercomputer BioHive-2, which the company says is the largest supercomputer in pharmaceutical industry.
RXRX is currently trading at $9.65, up $1.05 or 12.22%, on the Nasdaq. The stock opened its trading at $9.40 after closing Friday at $8.60. The stock has traded between $4.92 and $16.75 in the past 52-week period.
Recursion announced the completion of BioHive-2, Recursion's new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs interconnected by NVIDIA Quantum-2 InfiniBand networking.
This NVIDIA-powered AI supercomputer results in four times faster speeds than Recursion's original supercomputer, BioHive-1, in benchmark performance tests.
"Scaled data generation paired with scaled computation is required to leverage AI in a space as vast and complex as biology," said Ben Mabey, Chief Technology Officer at Recursion. "Recursion has spent the last decade generating and aggregating one of the largest biological and chemical datasets in the world, purpose-built for training new AI models. With BioHive-2 now online, we have significantly more computational horsepower to accelerate our use of our ever-growing dataset, extending our ability to train larger and more generalizable foundation models and AI agents to industrialize our drug discovery efforts."
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.